SPRY Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - ARS Pharmaceuticals Inc

Watchlist Manager

Watchlist

Price: 6 USD -0.99% Market Closed

Market Cap: $595.8m

	ARS Pharmaceuticals Inc NASDAQ:SPRY	US
B	Biotest AG F:BIO	DE
F	Franco-Nevada Corp F:3FO	CA
P	Paradeep Phosphates Ltd NSE:PARADEEP	IN
	Aero Energy Ltd F:J5B	CA
E	EROAD Ltd ASX:ERD	NZ
K	KCE Electronics PCL SET:KCE	TH

Profitability Summary

ARS Pharmaceuticals Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

77%

Sustainable 3Y Average Gross Margin

48%

Negative Operating Margin

-213%

Negative 3Y Average Operating Margin

-78 503%

Operating Margin is Increasing

-2 247% > -213%

Negative Net Margin

-203%

Negative 3Y Average Net Margin

-62 962%

Net Margin is Increasing

-1 700% > -203%

Negative Free Cash Flow Margin

-203%

Negative 3Y Average Free Cash Flow Margin

-68 182%

Free Cash Flow Margin is Increasing

-2 524% > -203%

Negative ROE

-92%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-2 124%

Declining ROIC

-176% > -501%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

77%

Sustainable 3Y Average Gross Margin

48%

Negative Operating Margin

-213%

Negative 3Y Average Operating Margin

-78 503%

Operating Margin is Increasing

-2 247% > -213%

Negative Net Margin

-203%